About OncoGenex



OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses

Tuesday, Dec 1 2015

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2015

Thursday, Nov 12 2015

OncoGenex Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference

Thursday, Nov 5 2015

OncoGenex to Report Third Quarter 2015 Financial Results on November 12, 2015

Thursday, Oct 29 2015

OncoGenex Announces EMA Support for Phase 3 AFFINITY Trial Protocol Amendment

Thursday, Oct 8 2015

OncoGenex Announces Completion of Patient Enrollment in Borealis-2™ Clinical Trial Evaluating Apatorsen in Relapsed or Refractory Metastatic Bladder Cancer

Wednesday, Sep 30 2015

OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients; Low Levels Correlate with Improved Survival in Those at Increased Risk for Poor Outcomes

Sunday, Sep 27 2015


External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue